Statistics

Total Visits

Views
Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.50

Select a period of time:

Number of views in the range

Views
Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.26

Views

Views
April 202512
May 20250
June 20250
July 202510
August 20251
September 20251
October 20252
Download CSV file
 untranslated
 untranslated

Top country views

Views
Hong Kong10
United States6
Brazil4
Spain2
Canada1
Italy1
Venezuela1
South Africa1
 

Top cities views

Views
Hong Kong10
Dallas2
Cape Town1
Contagem1
Council Bluffs1
Madrid1
Manteca1
Maracay1
Padova1
Passo Fundo1